- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06347614
Modified Radical Prostatectomy for Prostate Cancer Patients With Enlarged Prostate and Severe Lower Urinary Tract Symptoms: a Single-center, Retrospective Study (Two-step RP)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun yat-sen University Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Diagnosed as prostate cancer pathologically by prostate biopsy Evaluated as localized prostate cancer by imaging studies Prostate volume>70mL evaluated by transrectal ultrasonography or multi-parametric magnetic resonance imaging Gleason score≤ 4+3=7 Preoperative PSA<20ng/mL Estimated survival> 10 years; Informed consent is obtained from the patient
Exclusion Criteria:
The patient has received other therapy including radical radiotherapy, transurethral resection of the prostate, cryoablation, HIFU, etc.
Any contraindication of surgery or anaesthesia
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Two-step Radical Prostatectomy
|
The first step was the enucleation of the hyperplastic adenoma, followed by the anterograde radical prostatectomy of residual tissue
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biochemical Recurrence-free Survival
Time Frame: 5 years
|
Number of participants who are free of biochemical relapse after a specified duration of time.
Biochemical recurrence is measured by PSA levels.
Biochemical recurrence was defined as a measurable serum PSA concentration 0.2 ng/ml or greater.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Surgical time
Time Frame: Intraoperative
|
Defined as the time duration from the incision at the opening to the end of closing the incision
|
Intraoperative
|
|
Estimated blood loss
Time Frame: Intraoperative
|
Defined as all the blood loss counting during the surgery
|
Intraoperative
|
|
Hospital stay
Time Frame: From date of surgery until the date of discharge, an average of 7 days
|
Defined as the time duration between the first day after surgery to the day of discharge
|
From date of surgery until the date of discharge, an average of 7 days
|
|
Lower urinary tract symptoms
Time Frame: 1 months, 3 months, 6 months, 12 months after surgery
|
Evaluated with International Prostatic Symptom Score (IPSS).
1-7: Mild 8-19:Moderate 20-35: Severe
|
1 months, 3 months, 6 months, 12 months after surgery
|
|
Erectile function
Time Frame: 6 months, 12 months and 24 months after surgery
|
Evaluated with International Index of Erectile Function-5 (IIEF-5).The IIEF-5 score is the sum of the ordinal responses to the 5 items. 22-25: No erectile dysfunction 17-21: Mild erectile dysfunction 12-16: Mild to moderate erectile dysfunction 8-11: Moderate erectile dysfunction 5-7: Severe erectile dysfunction |
6 months, 12 months and 24 months after surgery
|
|
Positive surgical margin rate
Time Frame: Through study completion, an average of 5 year
|
Defined as the proportion of patients with positive surgical margin of the whole prostate and the margin between the hyperplastic adenoma and the residual gland evaluated by pathologists.
The location of positive margin will be documented.
|
Through study completion, an average of 5 year
|
|
Complication
Time Frame: Through study completion, an average of 5 year
|
All the complications which was evaluated relevant to the surgery will be documented and graded by Clavien-Dindo grade system.
|
Through study completion, an average of 5 year
|
|
Continence ContinenceContinence Continence Continence Continence Continence Continence Continence Continence
Time Frame: 2 weeks, 1 months, 3 months, 6 months, 12 months after surgery
|
Evaluated with the use of pad per day.
Using no more than 1 pad per day is defined as complete continence
|
2 weeks, 1 months, 3 months, 6 months, 12 months after surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-FXY-042
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Roswell Park Cancer InstituteAIM ImmunoTech Inc.Active, not recruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Two-step Radical Prostatectomy
-
Sun Yat-sen UniversityRecruiting
-
Lithuanian University of Health SciencesRecruitingProstate Cancer (Adenocarcinoma) | Radical Prostatectomy | Prostate Cancer (Diagnosis) | Prostate Specific Antigen | Prostate Cancer (Post Prostatectomy)Lithuania
-
University of LeipzigHeinrich-Heine University, Duesseldorf; University Hospital Heidelberg; Klinikum...Completed
-
Mayo ClinicTerminatedAdenocarcinoma | Prostatic NeoplasmsUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownCancer of the PROSTATEFrance
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Tampere University HospitalSeinajoki Central HospitalActive, not recruiting
-
University of MichiganCompleted
-
Hospices Civils de LyonCompleted
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil